CompletedNCT00000737
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
Medication studyAges 18+United StatesEating disorders
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Denver and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 56
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00000737
- Official title
Show the full official title
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
Recruitment & locations
CompletedDenver · Chicago · Wichita
6 more locations
- New Orleans
- Baltimore
- St Louis
- Brooklyn
- Portland
- Providence
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Allergy and Infectious Diseases (NIAID), a research institute.
Did this study involve medication?
Yes. The study involved medication, including Dronabinol and Megestrol acetate.
Who was this study for?
Listed age limits: from 18 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me